Breast Cancer

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research.

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

In certain patients with ESR1-mutant breast cancer, time to next treatment was slightly higher with Orserdu versus PFS in a phase 3 trial.

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune checkpoint inhibitors.

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.

Since 2000, antibody-drug conjugates have been approved by the Food and Drug Administration for various cancer types, such as breast cancer.

When you’ve had cancer do doctors assume every ailment is cancer for you?

From a Hollywood star sharing an uplifting update to the death of a three-time boxing champion, here’s what’s happening in the cancer space this week.

With more than 150 treatments being studied in clinical trials, what is on the horizon for antibody-drug conjugates in breast cancer?

I’ve learned to live in the present by avoiding clocks, a necessary change in my life after having breast cancer.

Reflecting on my first diagnosis of breast cancer at 36 weeks pregnant has made me feel grateful for the positive moments during that dark time.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

Aerobic exercise improved self-reported cognitive function in women undergoing chemotherapy for breast cancer but had no effect on objective cognitive function.